Brought to you by 
MedImmune gets $500mm with convertible debt placement
28 Aug 2003
Executive Summary
MedImmune (focuses on infectious diseases and cancer) has raised $500mm with the private placement of 20-year convertible notes to qualified institutional buyers under Rule 144A. The notes will convert into common stock, initially priced at $68.18 each.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Convertible Debt
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MedImmune gets $500mm with convertible debt placement
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice